13F Holdings
中文EN

CADL Candel Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1841387 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-335.6%
TTM EPS YoY-173.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-93.6%
ROA-65.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets37.7%
Debt / equity0.00x
Current ratio7.57x
Interest coverage-13.30x

Cash quality & payout

Operating cash flow / net income0.70x
Accruals ratio-19.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$125,000$125,000
R&D expense$30.50M$19.31M$24.51M$20.79M$15.18M
SG&A expense$17.77M$14.06M$13.88M$14.06M$10.67M
Operating income-$48.27M-$33.37M-$38.39M-$34.72M-$25.73M
Interest expense$2.12M$2.09M-$2.60M$1.71M—
Pretax income-$38.18M-$55.18M———
Income tax$0$0$0$0$0
Net income-$38.18M-$55.18M-$37.94M-$18.79M-$36.12M
EBITDA-$47.42M-$32.38M-$37.43M-$33.94M-$25.49M
EPS (basic)-0.72-1.74-1.31-0.65-1.91
EPS (diluted)-0.72-1.74-1.31-0.65-1.91
Weighted avg. shares (diluted)52.96M31.68M28.94M28.82M18.87M
Balance sheet
Cash & equivalents$119.73M$102.92M$35.68M$70.32M$83.07M
Current assets$121.39M$103.80M$36.80M$71.94M$84.94M
PP&E, net$1.64M$2.19M$3.21M$4.42M$3.84M
Total assets$125.19M$106.87M$41.20M$77.69M$89.20M
Current liabilities$9.00M$37.53M$14.18M$5.62M$5.36M
Short-term debt$0$9.89M$8.89M——
Long-term debt—$1.73M$11.63M—$560,000
Total debt—$11.63M$20.52M—$560,000
Total liabilities$73.27M$40.54M$28.46M$29.98M$25.07M
Shareholders' equity$51.92M$66.33M$12.74M$47.71M$64.14M
Net debt—-$91.29M-$15.15M—-$82.51M
Shares outstanding54.90M46.81M29.09M28.92M28.69M
Cash flow statement
Operating cash flow-$38.31M-$27.02M-$34.24M-$31.42M-$22.22M
Capital expenditure$587,000$16,000$457,000$1.30M$1.83M
Free cash flow-$38.90M-$27.04M-$34.70M-$32.72M-$24.05M
Investing cash flow-$560,000-$16,000-$280,000-$1.30M-$1.83M
Financing cash flow$56.10M$94.28M-$121,000$19.97M$71.80M
Depreciation & amortization$845,000$990,000$960,000$778,000$232,000
Stock-based compensation$3.82M$5.31M$3.09M$2.31M$2.96M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.